Using health technology assessment to inform insurance reimbursement of high technology medicines in China: an example of cancer immunotherapy Post date 15 June 2023 ← How health technology reassessment can support disinvestment in China’s national drug reimbursement list → Health technology assessment to inform decision making in China: progress, challenges, and sustainability